Home » Specialists » Dr Tan Sing Huang
MBBS (Singapore)
M.Med (Singapore)
MRCP (United Kingdom)
FAMS (Medical Oncology)
Oncocare Location:
LANGUAGES SPOKEN:
YEARS OF EXPERIENCE:
CLINICAL INTERESTS:
Dr Tan Sing Huang is a Senior Consultant Medical Oncologist who has more than 30 years of experience in managing a wide range of cancers. Her subspecialty interests are in Women’s Cancers such as Breast cancers and Gynecological cancers, Lung cancers, and Gastrointestinal cancers (colon, rectum, pancreas, liver, gastric).
She obtained her basic medical degree (MBBS) from the National University of Singapore in 1995. She obtained her MRCP (UK) and M. Med (Internal Medicine) degrees in 2001. She underwent Advanced Specialist Training from the Academy of Medicine (Singapore) attaining her Medical Oncology accreditation in 2004.
Before joining OncoCare Cancer Centre, she held the position of Senior Consultant in the Department of Hematology-Oncology National University Cancer Institute, Singapore (NCIS). She was also an Assistant Professor, at the Yong Loo Lin School of Medicine, National University of Singapore.
During her work at NCIS, she continued to take care of patients with a wide variety of cancers, including Breast cancers, Gynecological cancers, Lung cancers, and Gastrointestinal cancers (colon, rectum, pancreas, liver, gastric) although her primary interest is in Women’s Cancers. As a result of her clinical efforts in NUH, she was awarded the Sunny Side-Up and Sunny Side-Up WOW Awards for exemplary patient feedback.
She led the Senior Residency Education division in NCIS as its Program Director from 2012 till 2016, served as Co-Chairman for the NCIS Clinical Competency Committee, and also as a panel member for the national selection of Medical Oncology trainees. In addition, she participated as an examiner for undergraduate final medical exams. As a result of her contributions to education, she was awarded the NUH Teaching Excellence Award in 2014.
She held the post of Vice President of the Singapore Society of Oncology from 2013 till 2018.
She was also a long-standing current active Committee Member since 2011 and Deputy Chair of the National Healthcare Group Domain-Specific Ethics Review Board from 2020 to 2024. This National Healthcare Group committee reviews Medical Oncology clinical trial protocols for hospitals.
She was also the principal investigator of several multi-centre studies investigating new investigational drugs in HER2-positive breast cancers as well as being co-investigator of several multi-centre clinical trials in lung, colorectal, and breast cancers.
Her interest in translational research led to spending time with the RUNX research group in Singapore under a National Medical Research-Singapore (NMRC) Totalisator Medical Research Fellowship Award. She then went to Johns Hopkins Sidney Kimmel Comprehensive Cancer Centre in Baltimore in 2006-2007 where she was involved in epigenetics research and also gained clinical experience from attachments with the Breast Cancer Division of Johns Hopkins Medical Institute.
She has been awarded the Research-Investigator-Scientist Enabler (RISE) Grant Scheme Award from 2008 to 2010, and the Junior Investigator Protected Time Award in 2011. She won a Merit Award for her Oral Presentation at the 10th International Conference of The Asian Clinical Oncology Society in Seoul on oncogenic mutation profiling changes pre- and post-chemotherapy in breast cancers. She was given the National Medical Research Council Clinician Investigator Salary Support Program (CISSP) Award from 2012 to 2014. She went on to obtain several independent grants since 2008 studying methylation patterns, high-throughput oncogenic mutation profiling, and the effects of chemotherapy on cognition in cancer patients.
She has contributed chapters on chemotherapy treatment of metastatic breast cancer in international textbooks such as Diseases of the Breast. In addition, she has written and contributed to publications that have appeared in local and international journals including Clinical Cancer Research and Annals of Oncology.
Dr Tan is fluent in English, Mandarin, and Hokkien and can speak some Malay and Bahasa. She has taken care of patients from many regional and overseas regions including Indonesia, Vietnam, Myanmar, China, Bangladesh, Sri Lanka, India, and Russia.
She has also given many local and overseas talks as an invited speaker including in China, Vietnam, and Brunei. She has also chaired conferences and been an invited speaker for both local and overseas conferences.
A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Histologically Confirmed, Locally Advanced (Inoperable) or Metastatic Triple-Negative Breast Cancer (TNBC) (CAPItello-290).
Site Map | PDPA | Terms of Use | Disclaimer |
Contact Us | Career | Media Contact